04/2020 - Acting on uncertainty: real-life mixtures of endocrine disrupting chemicals
Exposure to multiple synthetic chemicals is a permanent feature of modern life. Many of these chemicals are suspected to disrupt endocrine systems of humans and animals. Endocrine disrupting chemicals (EDCs) act at very low concentrations and non-linearly, defying mainstream single-substance chemical regulation. Here we provide an analysis of findings from the first phase of the […]
04/2020 - Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another drug. These evolutionary trade-offs can be exploited using ‘evolutionary steering’ to control the tumour population and delay resistance. However, recapitulating cancer […]
04/2020 - Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4+ T cells to cytokines
Naïve CD4+ T cells coordinate the immune response by acquiring an effector phenotype in response to cytokines. However, the cytokine responses in memory T cells remain largely understudied. Here we use quantitative proteomics, bulk RNA-seq, and single-cell RNA-seq of over 40,000 human naïve and memory CD4+ T cells to show that responses to cytokines differ substantially between […]
04/2020 - The Endless Frontier? The Recent Increase of R&D Productivity in Pharmaceuticals
Studies on the early 2000s documented increasing attrition rates and duration of clinical trials, leading to a representation of a “productivity crisis” in pharmaceutical research and development (R&D). In this paper, we produce a new set of analyses for the last decade and report a recent increase of R&D productivity within the industry.